NCT06998628 Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis
| NCT ID | NCT06998628 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Tanta University |
| Condition | Rheumatoid Arthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-06-02 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 50 participants in total. It began in 2025-06-02 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints
Eligibility Criteria
Inclusion Criteria: * Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) \[9\] i.e., 28 joints disease activity score (DAS 28) \>2.6. * Patients receiving the conventional DMARDs. * Both sexes. * Age range between 18and 70 years old Exclusion Criteria: * Patients with retinal or cerebral hemorrhage. * Patients with renal and hepatic dysfunction. * Patients with hypersensitivity to study medications. * Pregnant and lactating females. * Patients receiving biological or synthetic DMARDs
Frequently Asked Questions
Who can join the NCT06998628 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06998628 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06998628 currently recruiting?
Yes, NCT06998628 is actively recruiting participants. Visit ClinicalTrials.gov or contact Tanta University to inquire about joining.
Where is the NCT06998628 trial being conducted?
This trial is being conducted at Damietta, Egypt.
Who is sponsoring the NCT06998628 clinical trial?
NCT06998628 is sponsored by Tanta University. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.